21928-50-7

Basic information

• Product Name: 4-[4-Chloro-3-(trifluoromethyl)phenyl]-4-piperidinol
• Synonyms: TIMTEC-BB SBB003024;4-[4-Chloro-3-(trifluoroMethyl)phenyl]-4-piperidinol, 97% 5GR;4-(4-Chloro-3-(trifluoroMethyl)phenyl)-4-piperidinol;4-[4-chloro-3-(trifluoromethyl)phenyl]-4-piperidin-1-iumol;LABOTEST-BB LT00441026;4(3-TRIFLUOROMETHYL-4-CHLOROPHENYL)-4-PIPERIDINOL;4-[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]-4-PIPERIDINOL;4-[4-chloro-3-(trifluoromethyl)phenyl]piperidin-4-ol
• CAS NO: 21928-50-7
• Molecular Formula: C₁₂H₁₃ClF₃NO
• Molecular Weight: 279.69
• EINECS: 244-665-7
• Product Categories: API intermediates;Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;Piperidines;PiperidinesHeterocyclic Building Blocks
• Mol File: 21928-50-7.mol
• Article Data: 7

Chemical Properties

• Melting Point: 138-141 °C(lit.)
• Boiling Point: 333.3 °C at 760 mmHg
• Flash Point: 155.4 °C
• Appearance: Beige/Fine Crystalline Powder
• Density: 1.2685 (estimate)
• Vapor Pressure: 5.48E-05mmHg at 25°C
• Solubility: soluble in Methanol
• PKA: 13.55±0.20(Predicted)
• CAS DataBase Reference: 4-[4-Chloro-3-(trifluoromethyl)phenyl]-4-piperidinol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[4-Chloro-3-(trifluoromethyl)phenyl]-4-piperidinol(21928-50-7)
• EPA Substance Registry System: 4-[4-Chloro-3-(trifluoromethyl)phenyl]-4-piperidinol(21928-50-7)

Safety Data

• Hazard Codes: Xn
• Statements: 36/37/38-22
• Safety Statements: 22-24/25-37/39-26
• WGK Germany: 3
• Hazardous Substances Data: 21928-50-7(Hazardous Substances Data)

Usage

Chemical Properties

BEIGE FINE CRYSTALLINE POWDER

Uses

4-(4-Chloro-3-(trifluoromethyl)phenyl)-4-piperidinol may be used to synthesize piperidinols and penfluridol (a neuroleptic agent).

InChI:InChI=1/C12H13ClF3NO/c13-10-2-1-8(7-9(10)12(14,15)16)11(18)3-5-17-6-4-11/h1-2,7,17-18H,3-6H2/p+1

Upstream product

• 445-01-2 5-bromo-2-chlorobenzotrifluoride 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 21928-40-5 1-ethoxycarbonyl-4-(3-trifluoromethyl-4-chlorophenyl)-4-piperidinol 
• 29976-53-2 N-ethoxycarbonyl-4-piperidone 
• 863111-54-0 tert-butyl 4-(4-chloro-3-(trifluoromethyl)phenyl)-4-hydroxypiperidine-1-carboxylate 

Downstream Products

• 21928-40-5 1-ethoxycarbonyl-4-(3-trifluoromethyl-4-chlorophenyl)-4-piperidinol 
• 61271-42-9 1-[4,4-bis(p-fluorophenyl)cyclohexyl]-4-(4-chloro-3-trifluoromethylphenyl)-4-piperidinol hydrochloride 
• 1266656-52-3 1-(4,4-bis(4-(trifluoromethyl)phenyl)butyl)-4-(4-chloro-3-(trifluoromethyl)phenyl)piperidin-4-ol 
• 1266656-53-4 C₃₀H₃₃ClF₃NO 
• 1266656-54-5 C₃₀H₃₃ClF₃NO₃ 
• 1266656-55-6 C₃₀H₂₇ClF₉NO₃ 
• 1266656-57-8 C₃₀H₃₃ClF₃NO 
• 1266656-56-7 C₃₀H₂₇ClF₉NO 
• 1266656-50-1 4-(4-chloro-3-(trifluoromethyl)phenyl)-1-(4,4-diphenylbutyl)piperidin-4-ol 
• 905807-44-5 C₂₈H₂₇ClF₅NO 
• 1266656-85-2 1-(3,3-bis(4-fluorophenyl)allyl)-4-(4-chloro-3-(trifluoromethyl)phenyl)piperidin-4-ol 
• 26864-56-2 penfluridol 
• 50830-38-1 1-[4,4-bis(4-fluorophenyl)butyryl]-4-(3-trifluoromethyl-4-chlorophenyl)-4-piperidinol 
• 1266656-45-4 1-(5,5-bis(4-fluorophenyl)pentyl)-4-(4-chloro-3-(trifluoromethyl)phenyl)piperidin-4-ol 

Relevant articles and documents

Structure-Based Design and Synthesis of Piperidinol-Containing Molecules as New Mycobacterium abscessus Inhibitors

Non-tuberculous mycobacterium (NTM) infections, such as those caused by Mycobacterium abscessus, are increasing globally. Due to their intrinsic drug resistance, M. abscessus pulmonary infections are often difficult to cure using standard chemotherapy. We previously demonstrated that a piperidinol derivative, named PIPD1, is an efficient molecule both against M. abscessus and Mycobacterium tuberculosis, the agent of tuberculosis, by targeting the mycolic acid transporter MmpL3. These results prompted us to design and synthesize a series of piperidinol derivatives and to determine the biological activity against M. abscessus. Structure-activity relationship (SAR) studies pointed toward specific sites on the scaffold that can tolerate slight modifications. Overall, these results identified FMD-88 as a new promising active analogue against M. abscessus. Also, we determined the pharmacokinetics properties of PIPD1 and showed that intraperitoneal administration of this compound resulted in promising serum concentration and an elimination half-life of 3.2 hours.

Penfluridol preparation method

The invention discloses a penfluridol preparation method. The penfluridol preparation method includes the following steps of 1), subjecting succinic anhydride and fluorobenzene to Friedel-Crafts reaction prior to acid decomposition, and collecting a compound from the formula 2) as is shown in the description; 2), putting the compound in a solvent to collect a compound in formula 3) as is shown in the description in a solvent reduced through a reducing agent; 3), putting the compound into the fluorobenzene to perform the Friedel-Crafts reaction to collect a compound in the formula 4) as is shown in the description; subjecting the compound and ethyl chloroformate to action to generate a compound in formula 5) as is shown in the description; 5), subjecting the compound and a compound shown in formula (XVII) to reaction prior to hydrolyzation to collect a compound in formula 6) as is shown in the description; 6), performing reduction with the reducing agent prior to hydrolyzing a reduction product and then collecting penfluridol (I). The penfluridol preparation method is high in yield, low in cost, moderate in reaction condition, short in circuit, proper for industrial production, low in three wastes, easy to treat and suitable for industrial production.

DIPHENYLBUTYPIPERIDINE AUTOPHAGY INDUCERS

Autophagy inducing compounds, methods of their preparation and use, and kits containg said compounds are disclosed herein.